Proactive Investors - Run By Investors For Investors

Optibiotix and Knighton's to launch improved version of microbiome-based appetite suppressant Slimbiome

Knighton’s tehcnology will make SlimBiome easier to dissolve and enhancing its ease of use, flavour and mouthfeel
tape measure
Slimbiome enourages fat loss rather than just weight

Microbiome pioneer OptiBiotix Health PLC (LON:OPTI) will launch its revised formulation of hunger suppressant product SlimBiome, using a powder technology developed by new partner Knighton’s.

Knighton’s tehcnology will make SlimBiome easier to dissolve and enhances its ease of use, flavour and mouthfeel, said Optibiotix, and will open opportunities in bakeries, snacking, coffee shops and the growing ‘shakes’ market.

WATCH: Massive opportunities for OptiBiotix Health's new and improved SlimBiome

SlimBiome will be sold as an ingredient in white label format and will be highlighted in OptiBiotix's own brand the GoFigure range of shakes and bars.

AIM-listed Optibiotix wants to target the growing  'Health & Wellbeing' lifestyle trend and sees a huge possible range of applications with new flavours and applications such as muesli.

Knighton’s, part of Premier Foods, is one of a number partners that are using Slimbiome to develop products such as cookies, tortillas, breakfast cereals, food toppings, yoghurts and cereal bars.

Eventually, the plan is to ‘white label’ Slimbiome to large retailers, and branded consumer products manufacturers as well as food manufacturers.

READ: OptiBiotix licenses weight-loss technology to Premier Foods offshoot

Slimbiome has been developed from Optibiotix’s work on the human microbiome, the bacteria that inhabits the gut and skin and that is increasingly being recognised as playing a critical part in the way the human body processes food.

 Stephen O'Hara, Optibiotix chief executive, said: “We anticipate SlimBiome being the first in a family of products to include: ImmunBiome, WellBiome, OptiBiome and CardioBiome, developed using our advanced microbiome modulating technology platforms.”



View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use